Ospemifene: what it treats, how to take it, side effects
Last updated September 3, 2026.
Ospemifene is an estrogen-like medication - it replaces some of the estrogen effect the body stops making at menopause, targeted at vaginal tissue. You may know it as Osphena. A daily tablet for two specific symptoms - with a warning list that belongs in the decision.
What does it treat?
Painful sexual intercourse and vaginal dryness due to menopause.
How do you take it?
One tablet once a day with food, same time daily - exactly as directed. It controls symptoms; it does not cure the underlying change - the review of whether you still need it is a standing item with your doctor. Missed dose: take it when you remember unless the next one is close; never double up.
Side effects to know
- Common: hot flashes or flushes, vaginal discharge, muscle spasms, and increased sweating.
- Serious - call your doctor immediately: any unusual vaginal bleeding - the endometrial-cancer warning makes this the rule, not a wait-and-see; and the allergic set - hives, rash, itching, hoarseness, difficulty swallowing or breathing, swelling of the face, throat, tongue, lips, or eyes. The clot set rides the class: one swollen, warm, painful leg; sudden shortness of breath; chest pain.
Who should not take it?
Any history of cancer or abnormal vaginal bleeding generally rules it out - the warning is explicit. Flag clotting history, stroke or heart-attack history, and liver disease. Every other medication gets checked. This drug is only for after menopause.
When is it an emergency?
One swollen, warm, painful leg, sudden shortness of breath, chest pain, or face or throat swelling is a 911 call. For an overdose, call Poison Control at 1-800-222-1222. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Why the endometrial-cancer warning?
Estrogen-like drugs act on the uterine lining, and unopposed estrogen-type stimulation raises endometrial-cancer risk - the label is explicit: cancer history or abnormal vaginal bleeding generally rules the drug out, and any unusual vaginal bleeding while taking it is a call-your-doctor-immediately event. The warning is the reason the symptom is never waited out - not even once.
Is it the same as hormone replacement therapy?
Same neighborhood, narrower target: ospemifene acts estrogen-like mainly on vaginal tissue - it is for painful sex and dryness, not the full menopause-symptom portfolio. Hot flashes can actually appear as a side effect. The choice between it, local estrogen, and full HRT is a real fork: symptoms, history, and risk profile decide it with your doctor.
What about the clot risk?
The class carries it: estrogen-like drugs shift clotting. The emergency geography is specific: one leg swollen, warm, and painful; sudden shortness of breath; chest pain - 911, never a wait. Clotting, stroke, or heart-attack history goes on the table before the first dose.
Why is it reviewed every year?
Because the need changes: symptoms evolve, the risk ledger does not - the annual review re-asks "still worth it?" with current facts. That review is part of the prescription, not a courtesy. The drug controls symptoms; it does not cure the underlying change - so the question stays open by design.
Are the hot flashes a bad sign?
Listed and common: hot flashes or flushes, vaginal discharge, muscle spasms, and increased sweating are the mild set - ironic only on paper, and usually manageable. They are worth a mention at the next visit if they persist. The symptom that is never a wait-and-see on this drug is unusual bleeding - different category entirely.
What happens if I miss a dose of ospemifene?
Take it as soon as you remember, unless it is almost time for the next one - then skip it and never double up. The with-food, same-time anchor - breakfast is the natural one - keeps the question rare. One missed day barely moves the month; a pattern is worth a mention at the annual review.